PhotoPharmics announced that it has achieved full enrollment of 350 participants in its fully remote, home-based Phase 3 “Light for PD” clinical trial of its device, Celeste®, designed to treat both motor and non-motor symptoms of Parkinson’s disease. According to the company, the trial’s size and remote design mark it as one of the largest decentralized medical device studies ever conducted in this patient population.
The company said that Celeste delivers specialized wavelengths of light through the eyes to stimulate retinal pathways linked to brain regions that regulate sleep, mood, and neural signaling—areas affected in Parkinson’s. According to PhotoPharmics, the trial enables participants to use the device at home with telemedicine oversight, removing geographic barriers and improving accessibility while maintaining rigorous clinical monitoring.
PhotoPharmics claims that the accelerated enrollment underscores strong patient interest and demonstrates the feasibility of large-scale decentralized trials for neurodegenerative disease therapies. The company said that top-line data from the study are expected in mid-2026, with results anticipated to guide potential regulatory clearance and commercialisation of its light-therapy device.
The company stated that the completion of enrollment sets the stage for the next phase of its development strategy, as it continues to scale device manufacturing, engage clinicians and prepare for global market entry of phototherapy solutions for Parkinson’s and other neurological disorders.
